Sodium hyaluronate Pregnancy and Breastfeeding Warnings
Brand names: Durolane, Euflexxa, Gelsyn-3, Hyalgan, Supartz, Supartz FX
Medically reviewed by Drugs.com. Last updated on Aug 14, 2023.
Sodium hyaluronate Pregnancy Warnings
Safety has not been established.
US FDA pregnancy category: Not assigned.
Risk Summary: Animal studies have failed to reveal evidence of fertility impairment or teratogenicity.
It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.
Sodium hyaluronate Breastfeeding Warnings
Safety has not been established.
Excreted into human milk: Unknown
Excreted into animal milk: Yes
Comments:
-The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Hyalgan (sodium hyaluronate)." Sanofi Winthrop Pharmaceuticals
- (2001) "Product Information. Supartz (sodium hyaluronate)." Smith and Nephew Wound Management Division
References for breastfeeding information
- "Product Information. Hyalgan (sodium hyaluronate)." Sanofi Winthrop Pharmaceuticals
- (2001) "Product Information. Supartz (sodium hyaluronate)." Smith and Nephew Wound Management Division
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
